Have a feature idea you'd love to see implemented?
Let us know!
LTRN Lantern Pharma Inc
Price (delayed)
$2.95
Market cap
$31.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.78
Enterprise value
$24M
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial intelligence by
Highlights
The quick ratio has plunged by 61% YoY but it has grown by 8% from the previous quarter
The equity has contracted by 41% YoY and by 14% from the previous quarter
The company's debt rose by 33% QoQ and by 6% YoY
Key stats
What are the main financial stats of LTRN
Market
Valuations
Earnings
Shares outstanding
10.78M
Market cap
$31.81M
Enterprise value
$24M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$19.09M
EBITDA
-$18.91M
Free cash flow
-$17.24M
Per share
Balance sheet
Liquidity
EPS
-$1.78
Free cash flow per share
-$1.6
Book value per share
$2.47
Revenue per share
$0
TBVPS
$2.81
Total assets
$30.29M
Total liabilities
$3.7M
Debt
$291,244
Equity
$26.6M
Working capital
$26.32M
Debt to equity
0.01
Current ratio
8.31
Quick ratio
7.79
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-51.2%
Return on equity
-56.9%
Return on invested capital
-103.2%
Return on capital employed
-71.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LTRN stock price
How has the Lantern Pharma stock price performed over time
Intraday
0.34%
1 week
-15.47%
1 month
-12.2%
1 year
-25.88%
YTD
-31.07%
QTD
-19.62%
Financial performance
How have Lantern Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.2M
Net income
-$19.09M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 26% year-on-year and by 8% since the previous quarter
The company's net income fell by 26% YoY and by 8% QoQ
Growth
What is Lantern Pharma's growth rate over time
Valuation
What is Lantern Pharma stock price valuation
P/E
N/A
P/B
1.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Lantern Pharma's EPS has decreased by 27% YoY and by 8% from the previous quarter
LTRN's price to book (P/B) is 41% lower than its 5-year quarterly average of 2.0 and 30% lower than its last 4 quarters average of 1.7
The equity has contracted by 41% YoY and by 14% from the previous quarter
Efficiency
How efficient is Lantern Pharma business performance
The ROE has plunged by 90% YoY and by 23% from the previous quarter
Lantern Pharma's return on assets has shrunk by 80% YoY and by 20% QoQ
The return on invested capital has declined by 33% year-on-year and by 10% since the previous quarter
Dividends
What is LTRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LTRN.
Financial health
How did Lantern Pharma financials performed over time
The quick ratio has plunged by 61% YoY but it has grown by 8% from the previous quarter
The current ratio has dropped by 61% year-on-year but it has grown by 8% since the previous quarter
The company's debt is 99% lower than its equity
The equity has contracted by 41% YoY and by 14% from the previous quarter
The company's debt rose by 33% QoQ and by 6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.